63 / 68
Patología retinal en pacientes VIH, aproximación diagnóstica y terapéutica del Citomegalovirus
63
1.
Ablashi DV, Sturzenegger S, Hunter EA et al. Presence
of HTLV-III in tears and cells from the eyes of AIDS
patients. J Exp Pathol 1987; 3:693-703.
2.
Fujikawa LS, Salahuddin SZ, Ablashi D et al. Human
T-cell leukemia/lymphotropic virus type III in the
conjunctival epithelium of a patient with AIDS. Am J
Ophthalmol 1985; 100:507-509.
3.
Fujikawa LS, Salahuddin SZ, Palestine AG et al. Isolation
of human T-cell leukemia/lymphotropic virus type III
(HTLV-III) from the tears of a patient with acquired
immunodeficiency syndrome (AIDS). Lancet 1985; 2:529.
4.
Freeman WR, Chen A, Henderly D et al. Prognostic and
systemic significance of non-infectious AIDS associated
retinopathy. Invest Ophthalmol Vis Sci 1987; 28(suppl):9.
5.
Cole EL, Meisler DM, Calabrese LH et al. Herpes zoster
ophthalmicus and acquired immune deficiency syndrome.
Arch Ophthalmol 1984; 102:1027-1029.
6.
(Sandor EV, Millman A, Croxson TS et al. Herpes zoster
ophthalmicus in patients at risk for the acquired immune
deficiency syndrome (AIDS). Am J Ophthalmol 1986;
101:153-155
7.
Holland GN, Pepose JS, Pettit TH et al. Acquired
immune deficiency syndrome, ocular manifestations.
Ophthalmology 1983; 90:859- 873.
8.
Geier SA, Schielke E, Klauss V et al. Retinal
microvasculopathy and reduced cerebral blood flow
in patients with acquired immunodeficiency syndrome.
Am J Ophthalmol 1992; 113:100-101
9.
Rosenberg PR, Uliss AE, Friedland GH et al. Acquired
immunodeficiency syndrome: ophthalmic manifestations
in ambulatorypatients. Ophthalmology 1983; 90:874-878.
10. Pepose JS, Nestor MS, Holland GN et al. An analysis of
retinal cotton-wool spots and cytomegalovirus retinitis
in the acquired immunodeficiency syndrome. Am J
Ophthalmol 1983; 95:118-119
11. Newsome DA, Green W, Miller ED et al. Microvascular
aspects of acquired immune deficiency syndrome
retinopathy. Am J Ophthalmol 1984; 98:590-601
12. Holland GN, Pepose JS, Pettit TH et al. Acquired
immune deficiency syndrome, ocular manifestations.
Ophthalmology 1983; 90:859-873.
13. Newsome DA, Green W, Miller ED et al. Microvascular
aspects of acquired immune deficiency syndrome
retinopathy. Am JOphthalmol 1984; 98:590-601
14. Review of draft for revision of HIV infection classification
system and expansion of AIDS surveillance case definition.
MMWR Morb Mortal Wkly Rep 1991; 40:787.
15. Collaborative DHPG Treatment Study Group. Treatment of
serious cytomegalovirus infections with 9-(1,3-dihydroxy-
2-propoxymethyl) guanine in patients with AIDS and other
immunodeficiencies. N Engl J Med 1986; 314:801-805
16. Collaborative DHPG Treatment Study Group. Treatment of
serious cytomegalovirus infections with 9-(1,3-dihydroxy-
2-propoxymethyl) guanine in patients with AIDS and other
immunodeficiencies. N Engl J Med 1986; 314:801-805
17. Cunningham ET Jr, Levinson RD, Jampol LM et al. Ischemic
maculopathy in patients with acquired immunodeficiency
syndrome. AmJ Ophthalmol
2001; 132:727-733
18. Levinson RD, Dunn JP, Holland GN. Ophthalmic
disorders associated with selected primary and acquired
immunodeficiency diseases. In: Duane’s clinical
ophthalmology, Chapter 40. CD-ROM. Hagerstown:
Harper and Row, 2004
19. Berthe P, Baudouin C, Garraffo R et al. Toxicologic and
pharmacokinetic analysis of intravitreal injections of
foscarnet, either alone or in combination with ganciclovir.
Invest Ophthalmol Vis Sci 1994; 35:1038-1045.
20. Jabs DA, Martin BK, Forman MS. Cytomegalovirus
resistance to ganciclovir and clinical outcomes of
patients with cytomegalovirus retinitis. Ophthalmol
2003; 135:26-34.
BIBLIOGRAFÍA